Evidence map›Paper›PMID 27105307›Full record

ArticleAutophagy2016

Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer.

Theo S Plantinga, Marika H Tesselaar, Hans Morreau, Eleonora P M Corssmit, Brigith K Willemsen, Benno Kusters, A C H van Engen-van Grunsven, Johannes W A Smit, Romana T Netea-Maier

Open access · hybridAbstract read
In one paragraph

Article in Autophagy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Theo S Plantingaa Department of Internal Medicine , Radboud University Medical Center , Nijmegen , The Netherlands.
Marika H Tesselaara Department of Internal Medicine , Radboud University Medical Center , Nijmegen , The Netherlands.
Hans Morreaud Department of Pathology , Leiden University Medical Center , Leiden , The Netherlands.
Eleonora P M Corssmite Department of Endocrinology and Metabolic Diseases , Leiden University Medical Center , Leiden , The Netherlands.
Brigith K Willemsenc Department of Pathology , Radboud University Medical Center , Nijmegen , The Netherlands.
Benno Kustersc Department of Pathology , Radboud University Medical Center , Nijmegen , The Netherlands.
A C H van Engen-van Grunsvenc Department of Pathology , Radboud University Medical Center , Nijmegen , The Netherlands.
Johannes W A Smita Department of Internal Medicine , Radboud University Medical Center , Nijmegen , The Netherlands.
Romana T Netea-Maiera Department of Internal Medicine , Radboud University Medical Center , Nijmegen , The Netherlands.
Radboud University Medical Center · NLRadboud University Nijmegen · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although non-medullary thyroid cancer (NMTC) generally has a good prognosis, 30-40% of patients with distant metastases develop resistance to radioactive iodine (RAI) therapy due to tumor dedifferentiation. For these patients, treatment options are limited and prognosis is poor. In the present study, expression and activity of autophagy was assessed in large sets of normal, benign and malignant tissues and was correlated with pathology, SLC5A5/hNIS (solute carrier family 5 member 5) protein expression, and with clinical response to RAI ablation therapy in NMTC patients. Fluorescent immunostaining for the autophagy marker LC3 was performed on 100 benign and 80 malignant thyroid tissues. Semiquantitative scoring was generated for both diffuse LC3-I intensity and number of LC3-II-positive puncta and was correlated with SLC5A5 protein expression and clinical parameters. Degree of diffuse LC3-I intensity and number of LC3-II-positive puncta scoring were not discriminative for benign vs. malignant thyroid lesions. Interestingly, however, in NMTC patients significant associations were observed between diffuse LC3-I intensity and LC3-II-positive puncta scoring on the one hand and clinical response to RAI therapy on the other hand (odds ratio [OR] = 3.13, 95% confidence interval [CI] =1.91-5.12, P = 0.01; OR = 5.68, 95%CI = 3.02-10.05, P = 0.002, respectively). Mechanistically, the number of LC3-II-positive puncta correlated with membranous SLC5A5 expression (OR = 7.71, 95%CI = 4.15-11.75, P<0.001), number of RAI treatments required to reach remission (P = 0.014), cumulative RAI dose (P = 0.026) and with overall remission and recurrence rates (P = 0.031). In conclusion, autophagy activity strongly correlates with clinical response of NMTC patients to RAI therapy, potentially by its capacity to maintain tumor cell differentiation and to preserve functional iodide uptake.

Indexed as

AutophagyCarcinoma, PapillaryHumansIodine RadioisotopesPrognosisSodium-Iodide SymportersSymportersThyroid Cancer, PapillaryThyroid NeoplasmsIodine RadioisotopesSodium-Iodide SymportersSymportersautophagyLC3punctaradioactive iodine therapythyroid carcinoma

Identifiers

PMID27105307
PMCPMC4990989
OpenAlexW2341466915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.